May 20, 2020
1 min read
Save

Managing meals reduces diabetes-related mortality, experts issue osteoporosis guidance — top stories in endocrinology

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A bigger breakfast paired with a smaller dinner may reduce the risk for death in patients with diabetes, according to a recent study published in Diabetes Care. This was the top story in endocrinology last week.

Another top story was about new guidance from leading bone heath organizations on managing fracture risk in patients with osteoporosis during COVID-19.

Read these and more top stories in endocrinology below:

Smaller dinner, bigger breakfast may reduce risks for death from diabetes, CVD

People with diabetes who ate more at dinner compared with breakfast had greater risks for death from diabetes and CVD; however, a model suggests replacing 5% of total energy intake at dinner with breakfast can reduce mortality risks, according to findings published in Diabetes Care. Read more.

'Don't forget osteoporosis': Experts outline guidance for managing fracture risk during COVID-19

Leading bone health organizations have issued guidance for health care professionals treating people with osteoporosis during the COVID-19 pandemic, outlining important treatment adjustments for osteoporosis therapies and alternative methods for assessing fracture risk in the absence of a DXA scan. Read more.

Higher-dose dulaglutide reduces HbA1c, body weight in type 2 diabetes

Adults with poorly controlled type 2 diabetes assigned higher, investigational doses of the GLP-1 receptor agonist dulaglutide (Trulicity, Eli Lilly) experienced greater improvements in glycemic response and body weight compared with those assigned the currently approved dose of 1.5 mg weekly, with no new safety signals observed, according to findings from the AWARD-11 trial published in the Journal of the Endocrine Society. Read more.

HbA1c likely mediates liraglutide’s CV benefit

Change in HbA1c is likely the greatest mediator of the effect of the GLP-1 receptor agonist liraglutide on CVD for adults with poorly controlled type 2 diabetes who are at high CV risk, according to findings from an exploratory analysis of the LEADER trial published in Diabetes Care. Read more.

Lower BMI, greater weight loss before bariatric surgery decrease risk for 30-day mortality

Among nearly half a million adults from the United States and Canada who underwent weight-loss surgery, those with lower presurgical BMI and those who lost even a small amount of weight before the procedure were less likely to die within 30 days, according to findings published in JAMA Network Open. Read more.